Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Kivu Bioscience Inc.
Exscientia AI Limited
Sotio Biotech Inc.
MacroGenics
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
Incyte Corporation
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Incyte Corporation
Theratechnologies
AstraZeneca
BeiGene
Carisma Therapeutics Inc
Xencor, Inc.
MacroGenics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Gossamer Bio Inc.
Genocea Biosciences, Inc.
AbbVie
Incyte Corporation
Incyte Corporation
AstraZeneca
Celgene
Canadian Cancer Trials Group
MedImmune LLC
University of Wisconsin, Madison
Oncology Institute of Southern Switzerland
Merrimack Pharmaceuticals
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Santa Maria Biotherapeutics
Virginia Commonwealth University
Yale University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Duke University
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Roger Williams Medical Center
NYU Langone Health
Mannkind Corporation
Case Comprehensive Cancer Center
Christiana Care Health Services